Phase 4 N=92 Acute Psychotherapy for Bipolar II Depression
Bipolar Disorder · Depression
Primary: Remission — 16; 13 Participants — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=41 Iloperidone in Mixed States of Bipolar Disorder
Bipolar Disorder
Primary: Measure of Response by Change From Baseline to End of Study in BISS Depression and Mania Scale Scores — 35.7; 61.8; 25; 48 percentage change in score on BISS scale…
Phase 3 N=25 Psychotherapy for Bipolar II Depression, Pilot Study, Phase II
Bipolar II Disorder
Primary: Number of Participants With Greater Than or Equal to 50% Reduction in Depression Scores, With a Mania Score Less Than or Equal to 10 — 4; 3; 10; 8 participants
Phase 3 N=54 Double-blind, Placebo-Controlled Divalproex Sodium ER in Bipolar I or Bipolar II Depression
Bipolar Disorder
Primary: Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -9.64; -5.32 units on a scale
Phase 4 N=129 Antidepressant Therapy in Treating Bipolar Type II Major Depression
Bipolar Disorder · Depression
Primary: Depressive Relapse — 3; 4 Participants
Phase 4 N=21 Brexpiprazole for Bipolar Depression
Bipolar Depression
Primary: The Montgomery-Asberg Depression Rating Scale (MADRS) — 31.95; 9.95; 10.95 score on a scale — p=<.001
N/A N=20 Bipolar Intervention Study: Cognitive Interpersonal Therapy
Mania · Hypomania · Bipolar Affective Disorder
Primary: Montgomery Asberg Depression Rating Scale (MADRS) (Montogomery and Asberg, 1979) — 26.20; 20.20; 16.11; 15.22 units on a scale — p=0.05
N/A N=29 Pilot Study of Cognitive Behavioral Therapy for Anxiety and Bipolar I Disorder
Bipolar Disorder · Anxiety Disorders
Primary: Reductions Over Time in Anxiety Symptoms as Measured by Hamilton Anxiety Rating Scale — 14; 18.81; 11.78; 17.70 Units on scale — p=.02
Phase 3 N=57 Lamotrigine for Symptoms of Geriatric Bipolar Depression
Bipolar Disorder · Depression, Bipolar
Primary: Assessment of Change in Depressive Symptoms From Baseline on the Montgomery Asberg Depression Rating Scale (MADRS) — -15.5 units on a scale — p=<.01
Phase 3 N=414 Evaluation of Efficacy and Safety of Iloperidone in the Acute Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder
Bipolar I Disorder
Primary: Change From Baseline to Week 4 in Young Mania Rating Scale (YMRS) Total Score — -14.0; -10.0 Change from Baseline in YMRS Total Score
Phase 3 N=224 Trial of Olanzapine in Patients With Manic or Mixed Episode of Bipolar I Disorder
Bipolar Disorder
Primary: Change From Baseline to 3 Week Endpoint in Young Mania Rating Scale (YMRS) Total Score — -12.6; -14.3; -6.8 units on a scale — p=<0.001
Phase 4 N=86 Maintenance Treatment of Bipolar Depression
Bipolar Disorder · Depression
Primary: Mania Rating Scale — 4.54; 5.57 units on a scale
Phase 3 N=554 Clinical Trial Evaluating ITI-007 (Lumateperone) as a Monotherapy for the Treatment of Bipolar Depression
Bipolar Depression
Primary: Change From Baseline to Day 43 in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score — -18.9; -20.7; -19.7 score on a scale — p=0.514
Phase 4 N=202 A Comparison of Olanzapine in Combination With a Mood Stabilizer vs Mood Stabilizer Alone, in Mixed Bipolar Patients
Bipolar I Disorder
Primary: Mean Change in Young Mania Rating Scale (YMRS) Scores From Baseline to Endpoint. — -10.15; -7.68 units on a scale — p=<0.001
Phase 4 N=189 Differentiating Unipolar and Bipolar Depression in Young Adults Using fMRI
Bipolar Disorder · Major Depression
Primary: HAM-D 17 Item: Hamilton Depression Rating Scale — 6.6; 4.91; 2.333; 3.75 score on a scale
N/A N=26 Decision-Making in Bipolar Disorder
Bipolar Disorder
Primary: Change in Vigilance Assessed by the Melbourne Decision Making Questionnaire (MDMQ) — .176 units on a scale
Phase 3 N=514 Olanzapine Treatment of Patients With Bipolar I Disorder
Depression, Bipolar
Primary: Change From Baseline to Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score (Acute Phase) — 29.36; 28.69; -14.26; -11.71 units on a scale — p=0.018
N/A N=44 Transcranial Direct Current Stimulation Therapy for Bipolar Depression
Depression, Bipolar · Bipolar Disorder · Mood Disorders
Primary: Number of Participants With Clinical Response [ Time Frame: At 6 Weeks Following Course of tDCS Treatment ] — 34 Participants
Phase 3 N=75 Aripiprazole for Bipolar Disorder and Alcohol Use Disorder
Bipolar Disorder · Alcoholism · Alcohol Abuse
Primary: Timeline Follow Back (TLFB) — -0.82; -0.71 drinks per drinking day
Phase 2 N=341 A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression
Depressive Episode · Bipolar 1 Depression
Primary: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 6 — -19.485; -19.324; -16.196 units on a scale — p=0.044
N/A N=92 Effect of Pharmaceutical Care in Patients With Bipolar I Disorder (BD I)
Bipolar Disorder
Primary: To Reduce the Use of Health Care Services by Quantifying the Number of Hospitalizations — 12; 1 Hospitalizations
Phase 3 N=258 A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group-comparison Trial of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode
Bipolar I Disorder
Primary: Young Mania Rating Scale (YMRS) — -11.3; -5.3 scores on a scale — p=<0.001
Phase 4 N=130 Citicoline for Bipolar 1 Disorder and Cocaine Dependence
Bipolar Disorder · Cocaine Dependence
Primary: Percentage of Participants With Presence of a Cocaine-Positive Urine Screen — 59.0; 49.2 percentage of participants
Phase 3 N=10 Study of Icariin for Bipolar Disorder and Co-Occurring Substance Use Disorders
Bipolar Disorder · Substance Use Disorder
Primary: Change in Hamilton Rating Scale of Depression (HAMD) From Baseline to Week 8 (Exit) — 17.5; 9 HAMD scale units — p=.012
Phase 4 N=40 Prediction of Clinical Response to SSRI Treatment in Bipolar Disorder Using Serotonin 1A Receptor PET Imaging
Bipolar Disorder
Primary: Montgomery-Asberg Depression Rating Scale — -39.24 Percent change in MADRS from baseline
Phase 2 N=35 A Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a Current Major Depressive Episode
Bipolar Disorder I · Bipolar Disorder II · Major Depressive Episode
Primary: Part A: Number of Participants With at Least One Treatment-Emergent Adverse Events (TEAEs) — 16 Participants
Phase 3 N=896 A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features
Bipolar I Disorder · Mania · Depression
Primary: Time to First Relapse of Any Mood Episode During the Double-Blind Treatment Period — NA; NA; NA; NA days — p=0.5745
Phase 3 N=525 A Phase III Study of SM-13496 in Patients With Bipolar I Depression.
Bipolar Depression
Primary: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 6 — -10.6; -13.6; -12.6 units on a scale — p=0.007
N/A N=19 Bipolar Disorder in Late Life
Bipolar Disorder
Primary: Boyko DWM Hyperintensity Value >2 in Subjects Who Received Acute Treatment for Mania — 10; 9 participants — p=>0.05
N/A N=10 iTBS in Bipolar I Depression
Bipolar Depression · Bipolar I Disorder
Primary: Change in Montgomery-Asberg Depression Rating Scale (MADRS) Score — 16.9 score on a scale